Genomics in Cancer Drug Discovery and Development

Edited by

  • Garret Hampton, Celgene Signal Research, San Diego, CA, U.S.A.
  • Karol Sikora, Professor, Hammersmith Hospital, Hammersmith, U.K.

Series Editor:

  • George Vande Woude, Director, Van Andel Research Institute, Grand Rapids, MI, USA
  • George Klein, Karolinska Insitutet, Stockholm, Sweden

The Advances in Cancer Research series provides invaluable information on the exciting and fast-moving field of cancer research. This volume stands as the first ever thematic volume in the series, focusing on the topic of genomics in cancer drug development. The chapters included in this book represent the cutting-edge information in the field and span such topics as Mass Spectrometry: Uncovering the Cancer Proteome for Diagnostics; Biomarker Discovery in Epithelial Ovarian Cancer by Genomic Approaches; The Application of siRNA Technology to Cancer Biology Discovery; Ribozyme Technology for Cancer Gene Target Identification and Validation; Cancer Cell-Based Genomic and Small Molecule Screens; Tumour Antigens as Surrogate Markers and Targets for Therapy and Vaccines; Practices and Pitfalls of Mouse Cancer Models in Drug Discovery; Biomarker Assay Translation from Discovery to Clinical Studies in Cancer Drug Development – Quantification of Emerging Protein Biomarkers; Molecular Optical Imaging of Therapeutic Targets of Cancer; Cancer Drug Approval in the United States, Europe and Japan.
View full description

Audience

Researchers and students in the basic and clinical science of cancer biology and oncology, plus related areas in genetics, immunology, pharmacology, cell biology and molecular biology.

 

Book information

  • Published: December 2006
  • Imprint: ACADEMIC PRESS
  • ISBN: 978-0-12-006696-4


Table of Contents

Mass Spectrometry: Uncovering the Cancer Proteome for Diagnostics.Biomarker Discovery in Epithelial Ovarian Cancer by Genomic Approaches.The Application of siRNA Technology to Cancer Biology Discovery.Ribozyme Technology for Cancer Gene Target Identification and Validation.Cancer Cell-Based Genomic and Small Molecule Screens.Tumour Antigens as Surrogate Markers and Targets for Therapy and Vaccines.Practices and Pitfalls of Mouse Cancer Models in Drug Discovery.Biomarker Assay Translation from Discovery to Clinical Studies in Cancer Drug Development – Quantification of Emerging Protein Biomarkers.Molecular Optical Imaging of Therapeutic Targets of Cancer.Cancer Drug Approval in the United States, Europe and Japan.